Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PDNMS
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 08 May 2018 New trial record